Abstract: A fiber optic telecommunications device includes an enclosure defining an interior. A first fiber optic adapter is provided at the enclosure. A spool is provided at an exterior of the enclosure. A fiber optic cable, which includes a first optical fiber, is wrapped around the spool. A first fiber optic connector is mounted at a first end of the first optical fiber. The first end of the first optical fiber is positioned within the interior of the enclosure. The first fiber optic connector is inserted within the first fiber optic adapter. The enclosure and the spool are configured to rotate in unison about a common axis when the fiber optic cable is unwound from the spool.

Abstract: A spinal joint distraction system for treating a facet joint including articular surfaces having a contour is disclosed and may include a delivery device including a generally tubular structure adapted to engage a facet joint, an implant adapted to be delivered through the delivery device and into the facet joint, the implant comprising two members arranged in opposed position, and an implant distractor comprising a generally elongate member adapted to advance between the two members of the implant causing separation of the members and distraction of the facet joint, wherein the implant is adapted to conform to the shape of the implant distractor and/or the articular surfaces of the facet upon being delivered to the facet joint. Several embodiments of a system, several embodiments of an implant, and several methods are disclosed including a method for interbody fusion.

Abstract: Content is organized for brands by selecting a plurality of brand templates. After each selection, a set of properties is generated by applying a portion of settings of the respective brand template, with the remaining settings being overridden with settings for a channel communicating one of a plurality of presentations to a node of a network involved in the communication. The plurality of presentations may include different renditions of the same content. The properties may include sections configured for different focus areas and/or types of content associated with at tags to enable brand-level-targeting. Filters may be identified in the properties. Based on each of the identifications, a property from among the generated sets of properties may be selected based on comparisons with the associated tags.

Abstract: A spinal joint distraction system for treating a facet joint including articular surfaces having a contour is disclosed and may include a delivery device including a generally tubular structure adapted to engage a facet joint, an implant adapted to be delivered through the delivery device and into the facet joint, the implant comprising two members arranged in opposed position, and an implant distractor comprising a generally elongate member adapted to advance between the two members of the implant causing separation of the members and distraction of the facet joint, wherein the implant is adapted to conform to the shape of the implant distractor and/or the articular surfaces of the facet upon being delivered to the facet joint. Several embodiments of a system, several embodiments of an implant, and several methods are disclosed including a method for interbody fusion.

Abstract: A therapy system includes a patient support apparatus and a pneumatic therapy device that is coupleable to the patient support apparatus. The therapy device may receive power and air flow from the patient support apparatus.

Abstract: Provided herein are compositions, systems, kits, and methods for detecting cardiovascular disease, risk of cardiovascular disease, and/or reverse cholesterol transport potential in a subject based on the levels of PIP2 phospholipid in the subject.

Abstract: Provided herein are compositions, systems, kits, and methods for performing an apoA1 exchange assay to determine the risk of MACE and/or for conducting an action based on the assay results. In some embodiments, methods are provided for generating, or receiving, a report that graphically displays: i) the subjects ApoA1 exchange rate in a sample as lower than a control or threshold value, and ii) the subjects risk of a major adverse cardiac event (MACE) and/or cardiovascular disease as being higher than normal.

Abstract: Provided herein are compositions, systems, kits, and methods for detecting cardiovascular disease, risk of cardiovascular disease, and/or reverse cholesterol transport potential in a subject based on the levels of PIP2 phospholipid in the subject.

Abstract: A source code processing application may process source code and realize the results of the code in a map configuration. In one example, the map may be displayed with a number of stations and pathways between the stations to illustrate associations with classes of the source code. An example method of operation may include one or more of retrieving source code comprising a class from memory, processing the source code to identify an error associated with the class, creating a map with a station linked to the error, and displaying the map on a device.

Abstract: Provided herein are compositions, systems, kits, and methods for detecting cardiovascular disease, risk of cardiovascular disease, and/or reverse cholesterol transport potential in a subject based on the levels of PIP2 phospholipid in the subject.

Abstract: A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.

Abstract: A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.

Abstract: A method of ameliorating one or more symptoms of an inflammatory condition in a subject comprises the step of administering to the subject a therapeutically effective amount of a polypeptide that is capable promoting cholesterol efflux from lipid loaded cells, the polypeptide consisting of the amino acid sequence of SEQ ID NO:1, in which each X in SEQ ID NO:1 is a phenylalanine amino acid.

Abstract: An excavator includes a mobile chassis with a first bucket drum and a second bucket drum coupled thereto. The first bucket drum and second bucket drum are coupled to the chassis for positioning thereof on the surface at opposing ends of the chassis. Each first scoop on the first bucket drum is a mirror image of one second scoop on the second bucket drum when (i) the first bucket drum and second bucket drum are on the surface adjacent opposing ends of the chassis, and (ii) the first bucket drum is rotated in one direction and the second bucket drum is simultaneously rotated in an opposing direction.

Abstract: Textured surface for increasing Leidenfrost temperature. The texture comprises of surface features over multiple length scales—from micro to nanoscale—wherein the features at each length scale have a size, aspect ratio, and spacing selected to increase the Leidenfrost temperature. The structure includes an array of microscale structures disposed on the surface, the structure having size, aspect ratio and spacing selected to increase Leidenfrost temperature. The microscale structures may also include nanoscale structures on their surface to create a hierarchical structure. The structures result in an increased Leidenfrost temperature.

Abstract: A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.

Abstract: A method for the treatment of cardiovascular disease or disorder in a subject in need thereof, the method comprising the steps of administering an ApoA1 mimetic that is capable of promoting cholesterol efflux from lipid loaded cells in the subject, wherein the ApoA1 mimetic has an amino acid sequence that includes at least a portion of the amino acid sequence of ApoA1 or a mimetic of ApoA1 that contains at least one tryptophan, at least one tryptophan from the ApoA1 or mimetic of the ApoA1 being substituted with an oxidant resistant amino acid in the amino acid sequence of the ApoA1 mimetic.

Abstract: A pharmaceutical composition for inhibiting amyloid beta peptide in a subject includes a compound having the formula (I): where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group; p is an integer from 0-3; X1 is a 3-9 atoms in length linker connecting A and B; B is selected from a substituted or unsubstituted aryl, alkoxy or amine group; and a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier.

Abstract: A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.